Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 89,300

Document Document Title
WO/2018/071655A1
Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and a...  
WO/2018/071701A1
In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need there...  
WO/2018/071741A1
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...  
WO/2018/069126A1
The invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and car...  
WO/2018/069148A1
The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardi...  
WO/2018/070069A1
The present invention provides a medicine comprising: a Toll-like receptor agonist; and LAG-3 protein, a variant thereof, or a derivative thereof.  
WO/2018/068182A1
The present disclosure provides antibodies and antigen binding fragments against CTLA4, which can block the binding of CTLA4 to its ligand. The antibodies of disclosure provide agents for treating diseases, such as cancer.  
WO/2018/068758A1
Disclosed is the medical use of an anti-c Met antibody-cytotoxic drug conjugate. In particular, disclosed are an anti-c-Met antibody, an antigen-binding fragment of c-Met, a chimeric antibody and humanized antibody comprising the anti-c-...  
WO/2018/070775A1
The present invention relates to a novel use of a veterinary composition comprising sulpyrine, and preferably sulpyrine and additional active ingredients. The veterinary composition according to the present invention is inoculated in a m...  
WO/2018/071452A1
Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at le...  
WO/2018/069924A1
The invention relates to a none cytotoxic combination therapy comprising at least one angiogenesis inhibitor, at least one non-steroidal anti-inflammatory agent, at least one NFk B inhibitor and at least one H2 blocker and a pharmaceutic...  
WO/2018/071548A1
The present disclosure relates to methods for treating Alzheimer's disease with apilimod and related compositions and methods.  
WO/2018/068832A1
There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said co...  
WO/2018/070390A1
The purpose of the present invention is to provide a pharmaceutical composition and the like used for treating or preventing angiogenic diseases. This pharmaceutical composition is a combination of a monoclonal antibody or antigen-bindin...  
WO/2018/070524A1
Provided are: a screening method suited for screening for a blood IgA production inhibitor, a blood IgA production accelerating agent, or a prophylactic or therapeutic agent against diseases caused by excessive IgA in the blood; a blood ...  
WO/2018/070774A1
When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of a...  
WO/2018/071437A1
The disclosure provides methods for treating vulvovaginal atrophy (WA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, ...  
WO/2018/069907A1
Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-...  
WO/2018/065028A1
Present invention relates to a composition for use in the treatment of an individual suffering from a condition necessitating new bone formation. The present invention further relates to osteoconductive carriers that have been provided w...  
WO/2018/066701A1
Provided is a prophylactic or therapeutic agent for frontotemporal lobar degeneration (FTLD), said agent comprising an inhibitor of calcium ion influx into cells. Also provided is a method for screening a prophylactic or therapeutic agen...  
WO/2018/067361A1
This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1...  
WO/2018/064922A1
Application of a GSK3 inhibitor in preparing a drug to treat Niemann-Pick disease type C, the GSK3 inhibitor being capable of significantly improving hematopoiesis and neural stem cell self-renewal and differentiation capability in NPC1 ...  
WO/2018/065219A1
A combination of drugs for use in a method for the prevention or treatment of cancer metastasis in an individual with a primary cancer is provided. The combination is administered to the individual and comprises a sub-anticoagulating hep...  
WO/2018/067769A1
The present disclosure provides, among other things, compounds, compositions, and methods useful for inhibiting bacteria, such as Mycobacterium tuberculosis. These compositions and methods find many uses in medicine and research, e.g., t...  
WO/2018/065778A1
The invention provides a combination comprising at least one compound selected from dichlorophen, chlorprothixene, perphenazine, thioridazine, trifluoperazine and edetate or a pharmaceutically acceptable derivative thereof and a carbapen...  
WO/2018/065771A1
The present invention relates to small molecule inhibitors of RAN at a transcriptional level and their use in the treatment of cancer, in particular cancers, such as triple negative breast cancer, that have been identified as overexpress...  
WO/2018/067948A1
Provided herein are antioxidant, thermally-responsive copolymer-based compositions and methods of making and using the compositions, e.g., for treatment of ischemia reperfusion injury in a patient. The copolymer comprises a hydrocarbyl b...  
WO/2018/065479A1
This disclosure relates to methods for making a composition of a cannabinoid and chicory flour. According to a method, the composition is manufactured by combining an amount of a cannabinoid and an amount of chicory flour comprising abou...  
WO/2018/067662A1
Provided herein are methods of testing a drug for efficacy for treating an amyloid disease. In exemplary embodiments, the methods comprises (i) contacting cells with the drug before or after the cells are contacted with a stimulus that c...  
WO/2018/066278A1
Provided is a pharmaceutical composition suitable for lymphogenous drug administration in which an anticancer drug is administered into a lymph node. The pharmaceutical composition which is for cancer therapy or prophylactic therapy and ...  
WO/2018/064589A1
The present application provides bifunctional compounds of Formula I or II: or an enantiomer, diastereomer, or stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present a...  
WO/2018/062134A1
The present invention provides a pharmaceutical composition for prophylaxis and treatment of NAFLD comprising as an active ingredient a 1,4-benzoxazine compound represented by formula (I): or a pharmaceutically acceptable salt thereof, a...  
WO/2018/060514A1
Methods and compositions for use for treating a precancerous lesion and/or a skin carcinoma, said composition comprising (i) at least one Pattern Recognition Receptor (PRR) agonist which potentiates IL12 secretion, and (ii) an anti-IL10 ...  
WO/2018/059739A1
The present invention describes a new method and new combination products for the therapy of neurological and other conditions which respond to dopaminergic therapies and especially to L-DOPA (L-Dihydroxy-Phenylalanine) based on the use ...  
WO/2018/057834A1
Disclosed herein are compositions comprising a combination of at least one Pol I inhibitor, and at least one autophagy inhibiting compound, and/or at least one ACAT1 inhibiting compound, and/or at least one PARP inhibiting compound and t...  
WO/2018/057723A1
This document relates to materials and methods for administering (e.g., topically administering) one or more vascular endothelial growth factor (VEGF) inhibitors to reduce and/or treat ultraviolet (UV)-induced skin injury. For example, c...  
WO/2018/055152A1
The present invention is directed to methods of modulating the function of granular immune effector cells. It has been discovered that the secretory lysosomes of immune effector cells function as signalling hubs which direct effector fun...  
WO/2018/056620A1
The present invention relates to a pharmaceutical combined composition for preventing or treating cancer comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof and topoisomerase inhibitor as active ingredients. ...  
WO/2018/056461A1
The present invention addresses the issue of providing a means to ameliorate deterioration in the quality of preimplantation embryos as a result of aging, etc. The present invention pertains to an agent for improving the quality of eggs,...  
WO/2018/055082A1
The present invention relates to an inhibitor of GPR132 for use in preventing and/or treating chemotherapy-induced neuropathic pain in a subject. Also encompassed by the invention are a pharmaceutical composition comprising an inhibitor ...  
WO/2018/056301A1
Provided is a cancer stem cell inhibitor containing, as an active ingredient, an inhibitor of the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/PPARγ coactivator 1β (PGC-1β)/pyruvate dehydrogenase α1 (PDHA1)/membrane associated ring...  
WO/2018/057737A1
The invention relates to methods for treating symptoms of PMS and PMDD including muscle ache, bloating, cramping, acne, tender breasts, bloating, fatigue, difficulty concentrating, diminished impulse control, irritability, anxiety, tensi...  
WO/2018/055211A1
The present invention pertains to the modification of the eukaryotic ubiquitin system by using the bacterial virulence factor SdeA and variants and mutants thereof. The invention is based on the phosphodiesterase activity of SdeA, which ...  
WO/2018/050686A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL pro...  
WO/2018/053397A1
The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a the...  
WO/2018/050782A1
The present invention concerns an antitumor pharmaceutical combination comprising (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.  
WO/2018/051250A1
Methods for treating HIV in a human using combinations of: tenofovir alafenamide, bictegravir, and 3TC, as well as compositions containing such compounds.  
WO/2018/050571A1
The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV caps...  
WO/2018/052120A1
This invention relates to compounds, compositions and methods for treating leukemia, such as acute myeloid leukemia, in subjects where one or more mutations in FLT3 kinase are present.  
WO/2018/053189A2
The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis an...  

Matches 1 - 50 out of 89,300